AOD-9604
Also known as Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
Regulatory Pathway
Dosing Protocol
Typical Dose
300 mcg daily
Frequency
Once daily, usually morning fasted
Duration
12-24 weeks
Timing & Administration
Administer via Subcutaneous injection or oral (both studied). Frequency: Once daily, usually morning fasted.
Popular Uses
Mechanism of Action
Mimics the lipolytic (fat-burning) effects of growth hormone without affecting blood sugar or tissue growth. Stimulates lipolysis and inhibits lipogenesis by interacting with beta-3 adrenergic receptors on fat cells.
Research Summary
Evidence level: clinical trials. Clinical status: Clinical trials completed - Did not achieve FDA approval for obesity.
Side Effects & Safety
Important Warnings
- No typical HGH side effects
- GRAS status by expert panel.
References
No references available.
Related Peptides
Browse all →A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.
View profileA dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.
View profileA triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.
View profile